1
Matvey E Lukashev, Gilmore O Neill: Treatment for multiple sclerosis. Biogen Idec MA, Sterne Kessler Goldstein & Fox P L L C, March 19, 2013: US08399514 (24 worldwide citation)

Provided are certain methods of screening, identifying, and evaluating neuroprotective compounds useful for treatment of neurological diseases, such as, e.g., multiple sclerosis (MS). The compounds described upregulate the cellular cytoprotective pathway regulated by Nrf2. Also provided are certain ...


2
Fred P Sherman, Elliot Hahn: Method of treatment for multiple sclerosis. Baker Cummins Pharmaceuticals, Kirschstein Ottinger Israel & Schiffmiller, February 19, 1991: US04994466 (15 worldwide citation)

A method of treating a patient suffering from multiple sclerosis comprising daily administration to such patient of from about 1 to about 100 mg of a pure narcotic antagonist, e.g., nalmefene or naltrexone. The antagonist may be administered in divided doses from one to four times daily, preferably ...


3

4
James B Mercer: Reagents and method for therapeutic treatment of multiple sclerosis. Litman McMahon & Brown, April 7, 1992: US05102902 (6 worldwide citation)

The administration internally to humans of certain imidazol derivatives, especially N"-cyano-N-methyl-N'-[2[[(5-methyl-1H-imidazol-4-yl) methyl]thio]-ethyl]-guanidine (cimetidine) or salts thereof, is an effective therapeutic treatment for multiple sclerosis, both acute and chronic. The imidazole mo ...


5
Michael C Mullenix, Robert Elliot Zipkin, Jeffrey Kroll Adams, Wayne Forrest Patton, James J Donegan: Hydroxycholesterol immunoassay. Enzo Life Sciences, Anna D DiGabriele Petti, March 3, 2015: US08969525 (2 worldwide citation)

Provided is a derivative of 22-hydroxycholesterol, 24S-hydroxycholesterol, 25-hydroxycholesterol, 26-hydroxycholesterol or 27-hydroxycholesterol. Also provided is a protein conjugated to the above derivative. Further provided is an antibody composition comprising antibodies that specifically bind to ...


6
STEIDL STEFAN: Treatment for multiple sclerosis. MORPHOSYS, Hutter Bernd, November 11, 2010: WO/2010/128035 (2 worldwide citation)

The present invention relates to methods for the treatment and/or prophylaxis of multiple sclerosis (MS). Antagonists of GM-CSF, such as antibodies specific for GM-CSF or the GM-CSF receptor, are effective in the treatment and/or prophylaxis of multiple sclerosis.


7
Smilek Dawn, Samson Michael, Gefter Malcolm, Hsu Di Hwei, Shi Jia Dong, Paliard Xavier, Devaux Brigitte, Rothbard Jonathan, Franzén Henry: Compositions and treatment for multiple sclerosis. Immulogic Pharmaceutical Corporation, Smilek Dawn, Samson Michael, Gefter Malcolm, Hsu Di Hwei, Shi Jia Dong, Paliard Xavier, Devaux Brigitte, Rothbard Jonathan, Franzén Henry, CRAIG Anne I, May 2, 1996: WO/1996/012737 (1 worldwide citation)

The present invention provides isolated peptides and combinations of peptides derived form myelin autoantigens such as MBP, MOG, PLP, and MAG suitable for treating multiple sclerosis, including prophylactic and therapeutic compositions and methods for preventing or treating multiple sclerosis. Prefe ...


8
Craig Smith, Peter S Chin: Methods for treating progressive multiple sclerosis. Genentech, Morrison & Foerster, June 20, 2017: US09683047

The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.


9
Constantine G Boojamra, Kuei Ying Lin, Richard L Mackman, David Y Markevitch, Oleg V Petrakovsky, Adrian S Ray, Lijun Zhang: Phosphonate analogs of HIV inhibitor compounds. Gilead Sciences, February 28, 2017: US09579332

The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.


10
Pieter Rottiers, Veerle Snoeck: Induction of mucosal tolerance to antigens. INTREXON ACTOBIOTICS, Drinker Biddle & Reath, January 10, 2017: US09539291

The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of Foxp3+ and/or IL-10 and/or TGF-β produc ...